Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Shenzhen Enduring Biotech Ltd. is a company patent portfolio currently managing 2 pending office actions. These matters are situated within the Biotechnology & Pharmaceuticals technology area. Prosecution is handled by 1 distinct examiner, which means that the current workload is not split among different individuals. This 1 distinct examiner operates within 1 distinct art unit.
CANELLA, KAREN A is the busiest examiner assigned to this company, with 2 pending office actions currently under review. This specific examiner count matches the total number of pending actions for the entire portfolio. The involvement of 1 distinct examiner across the pending actions means that the prosecution team interacts with a single official at the patent office. This arrangement can lead to a uniform application of examiner preferences across the cases.
The 1 distinct art unit involved indicates that the technical review is occurring within a single specialized group. Because CANELLA, KAREN A is responsible for 2 pending office actions, the examiner's perspective is central to the current status of the portfolio. The data reflects a prosecution environment where the Biotechnology & Pharmaceuticals filings are not distributed among multiple art units. Practitioners can focus their efforts on the specific prior art and technical standards recognized by this 1 art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 2 | 62.3% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18551136 | PEGYLATED T CELL ENGAGER WITH DUAL SPECIFICITIES TO CD3 AND CD19 | CANELLA, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18551136 | PEGYLATED T CELL ENGAGER WITH DUAL SPECIFICITIES TO CD3 AND CD19 | CANELLA, KAREN A | — |
| 17995541 | ANTIBODY-DRUG CONJUGATE | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18551136 | PEGYLATED T CELL ENGAGER WITH DUAL SPECIFICITIES TO CD3 AND CD19 | CANELLA, KAREN A | 1643 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 17995541 | ANTIBODY-DRUG CONJUGATE | CANELLA, KAREN A | 1643 | §103§112DP | Final Rejection | — | Pending | Oct 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Enduring Biotech Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karen A Canella has the most, with 2 of Shenzhen Enduring Biotech Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
